 |
|
In Reply
Arch Gen Psychiatry. 1999;56:415-416.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
WE APPRECIATE Dr Calabrese's commentary on our study of  3 fatty acids as a new treatment of bipolar disorder. He correctly points out both the exciting aspects of 3 fatty acids as a therapy for patients with bipolar disorder, as well as the methodological shortcomings of our preliminary trial.
Dr Calabrese's constructive criticisms of the study methodology are reasonable and are issues that future studies should address. When evaluating the methods for our current study, it is important to keep in mind that this was a preliminary study designed to demonstrate the prophylactic efficacy of 3 fatty acids as mood stabilizers. It was intended to be a longer-term trial, but 2 factors led to premature termination of the study. First, the preplanned 4-month interim data analysis revealed an unacceptably high relapse rate among the patients receiving placebo, which led us to conclude that it would be more ethical to stop . . . [Full Text of this Article]
RELATED ARTICLES
Omega 3 Fatty Acids in Bipolar Disorder: A Preliminary Double-blind, Placebo-Controlled Trial
Andrew L. Stoll, W. Emanuel Severus, Marlene P. Freeman, Stephanie Rueter, Holly A. Zboyan, Eli Diamond, Kimberly K. Cress, and Lauren B. Marangell
Arch Gen Psychiatry. 1999;56(5):407-412.
ABSTRACT
| FULL TEXT
Fish Oils and Bipolar Disorder: A Promising but Untested Treatment
Joseph R. Calabrese, Daniel J. Rapport, and Melvin D. Shelton
Arch Gen Psychiatry. 1999;56(5):413-414.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
A Natural Thymoleptic?
JWatch Psychiatry 1999;1999:4-4.
FULL TEXT
|
